Antimicrobial resistance of Helicobacter pylori in Smolensk | CMAC

Antimicrobial resistance of Helicobacter pylori in Smolensk

Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):42-48

​ Dekhnich N.N., Ivanchik N.V., Kozlov R.S., Alimov A.V., Steshits A.S., Kirsov P.P.
10.36488/cmac.2018.1.42-48
Helicobacter pylori antimicrobial resistance clarithromycin amoxicillin metronidazole levofloxacin
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(1):42-48

Objective.

To study the antimicrobial resistance of H. pylori to clarithromycin, amoxicillin, metronidazole, levofloxacin, tetracycline in adult patients in the Smolensk region.

Materials and Methods.

Overall, 573 adult patients were included in 2015-2017 and 210 – in 20092010 with positive rapid urease test at the time of gastroscopy for dyspeptic complaints. Antimicrobial susceptibility testing of H. pylori isolates to clarithromycin, amoxicillin, metronidazole, levofloxacin and tetracycline was performed by the agar dilution method.

Results.

143 and 133 strains of H. pylori isolated in 2015-2017 and in 2009-2010 were tested. The rates of resistance of H. pylori strains in 2015-2017 were 6.3% for clarithromycin, 1.4% – for amoxicillin, 23.8% – for metronidazole, 24.5% – for levofloxacin, 0.7% – for tetracycline. In 2009-2010 the corresponding numbers were: 5.3% – for clarithromycin, 4.5% – for amoxicillin, 3.8% – for metronidazole, 8.3% – for levofloxacin, 0% – for tetracycline. When assessing the dynamics of antimicrobial resistance of H. pylori in the Smolensk region over the past 9 years, there has been no noticeable increase in the resistance to clarithromycin, amoxicillin and tetracycline (p>0.05), with a significant increase in H. pylori resistance to metronidazole and levofloxacin (p<0,01). The resistance of H. pylori to metronidazole did not exceed the critical value of 40%.

Conclusions.

The prevalence of H. pylori resistance to clarithromycin and metronidazole in the Smolensk region was low throughout the study period, therefore standard triple therapy is recommended as a first line empirical therapy for H. pylori infection in adults. Preference in choosing a second-line empirical therapy between quadruple therapy with bismuth and triple therapy with levofloxacin should be stated in favor of quadruple therapy with bismuth because of the high rates of H. pylori resistance to levofloxacin.

Natalya N. Dekhnich

Smolensk State Medical University, Smolensk, Russia

Nataly V. Ivanchik

Smolensk State Medical University, Smolensk, Russia

Roman S. Kozlov

Smolensk State Medical University, Smolensk, Russia

Alimov A.V.

Clinical Hospital №1, Smolensk, Russia

Steshits A.S.

Smolensk Regional Clinical Hospital, Smolensk, Russia

Kirsov P.P.

Clinical Emergency Hospital, Smolensk, Russia

  • 1. Ivashkin V.T., Maev I.V., Lapina T.L., et al. Treatment of Helicobacter pylori infection: Mainstream and innovations. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2017;27(4):4-21. Russian.
  • 2. Bouvard V., Baan R., Straif K., et al. A Review of Human Carcinogens – Part B: Biological Agents. Lancet Oncol. 2009;10:321-322.
  • 3. Mabe K., Takahashi M., Oizumi H., et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol. 2009;15:4290-4297.
  • 4. Lee Y.C., Chiang T.H., Chou C.K., et al. Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology. 2016;150:1113-1124.
  • 5. Ma J.L., Zhang L., Brown L.M., et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104:488-492.
  • 6. Ohkusa T., Fujiki K., Takashimizu I., et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med. 2001;134:380-386.
  • 7. Wang J., Xu L., Shi R., et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: A meta-analysis. Digestion. 2011;83:253-260.
  • 8. McMahon B.J., Hennessy T.W., Bensler J.M., et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med. 2003;139:463-469.
  • 9. Fischbach L., Evans E.L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343-357.
  • 10. Malfertheiner P., Megraud F., O’Morain C., et al. Management of Helicobacter pylori infection – Maastricht V/Florence consensus report. Gut. 2017;66(1):6-30.
  • 11. Malfertheiner P., Megraud F., O’Morain C.A., et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut. 2012;61:646-664.
  • 12. Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34-42.
  • 13. Lim S.G., Park R.W., Shin S.J., et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Dig Liver Dis. 2016;48:385-390.
  • 14. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143-1153.
  • 15. Asaka M., Kato M., Takahashi S., et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1-20.
  • 16. Chen P.Y., Wu M.S., Chen C.Y., et al. Systematic review with metaanalysis: the efficacy of levofloxacin triple therapy as the first- or secondline treatments of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;44(5):427-437.
  • 17. Hsu P.I., Wu D.C., Chen A., et al. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur J Clin Invest. 2008;38:404-409.
  • 18. Nishizawa T., Suzuki H., Hibi T. Quinolone-based third-line therapy for Helicobacter pylori eradication. J Clin Biochem Nutr. 2009;44:119- 124.
  • 19. Grignon B., Tankovic J., Mégraud F., et al. Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Resist. 2002;8:61-66.
  • 20. Glupczynski Y., Broutet N., Cantagrel A., et al. Comparison of the E-test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2002;21:549-552.
  • 21. Kozlov R.S., Ivanchik N.V., Dekhnich N.N. Recommendations for the isolation, identification and sensitivity of Helicobacter pylori to antibacterial drugs. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2014;16(3):181-185. Russian.
  • 22. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0, 2018. Available at: www.eucast.org.
  • 23. Dekhnich N.N., Kostyakova E.A., Punin A.A., et al. Antibioticresistance of H. pylori: results of microbiologic regional investigation. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2011;21(2):37-42. Russian.
  • 24. BSAC Methods for Antimicrobial Susceptibility Testing. Version 8, 2009. Available at: bsac.org.uk.
  • 25. Pozdeev О.К., Morozova L.G., Pozdeeva А.О., et al. Primary antimicrobial resistance among Helicobacter pylori isolated in the republic of Tatarstan in the 2008-2013. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2016;18(2):146-151. Russian.
  • 26. Sablin O.A., Mihaylov N.V., Yurin M.V., et al. Helicobacter pylori primary resistance to antibiotics in St. Petersburg. Jeksperimental’naja i klinicheskaja gastrojenterologija. 2012;(8):18-23. Russian.
  • 27. Simanenkov V.I., Zakharova N.V., Zhebrun A.B., et al. Resistance of Helicobacter pylori to antimicrobial preparations by the results of bacteriologic testing. Lechashhij vrach. 2015;(4):91-95. Russian.
  • 28. Bluemel B., Goelz H., Eisele B. Primary resistance of Helicobacter pylori to clarithromycin, levofloxacin and tetracycline in Germany. Helicobacter. 2016;21(Suppl. 1):83.
  • 29. Gunnarsdottir A.I., Gudjonsson H., Hardardottir H., et al. Antibiotic susceptibility of Helicobacter pylori in Iceland. Infect Dis (Lond). 2017;49(9):647-654.
  • 30. Vekens K., Vandebosch S., De Bel A., et al. Primary antimicrobial resistance of Helicobacter pylori in Belgium. Acta Clin Belg. 2013;68(3):183-187.
  • 31. Boyanova L., Gergova G., Evstatiev I., et al. Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infect Dis (Lond). 2016;48(1):56-62.
  • 32. Di Giulio M., Di Campli E., Di Bartolomeo S., et al. In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy. Scan J Gastroenterol. 2016;51(3):263-269.
  • 33. Shiota S., Reddy R., Alsarraj A., et al.Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol. 2015;13:1616-1624.
  • 34. Mеgraud F., Ducournau A., Bеnеjat E., et al. Surveillance of Helicobacter pylori resistance to antibiotics in France in 2014. Helicobacter. 2016;21(Suppl. 1):110.
  • 35. Hashinaga M., Okimoto T., Kodama M., et al. Drug resistance in Japan; the present status of Helicobacter pylori; the totaled results of the resistant strain survey in 2013 and 2014. Jpn J Helicobacter Res. 2016;17:45-49.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared